Literature DB >> 17064280

HlyA knock out yields a safer Escherichia coli A0 34/86 variant with unaffected colonization capacity in piglets.

Valeria Sheshko1, Jana Hejnova, Zuzana Rehakova, Jiri Sinkora, Martin Faldyna, Pavel Alexa, Jurgen Felsberg, Radomira Nemcova, Alojz Bomba, Peter Sebo.   

Abstract

Escherichia coli A0 34/86 (O83:K24:H31) has been successfully used for prophylactic and therapeutic intestinal colonization of premature and newborn infants, with the aim of preventing nosocomial infections. Although E. coli A0 34/86 was described as a nonpathogenic commensal, partial sequencing revealed that its genome harbours gene clusters highly homologous to virulence determinants of different types of E. coli, including closely linked genes of the alpha-haemolysin operon (hlyCABD) and for the cytotoxic necrotizing factor (cnf1). A haemolysin-deficient mutant (Delta hlyA) of E. coli A0 34/86 was generated and its colonization capacity was determined. The results show that a single dose of the A0 34/86 wild-type or Delta hlyA strains resulted in efficient intestinal colonization of newborn conventional piglets, and that this was still considerable after several weeks. No difference was observed between the wild-type and the mutant strains, showing that haemolysin expression does not contribute to intestinal colonization capacity of E. coli A0 34/86. Safety experiments revealed that survival of colostrum-deprived gnotobiotic newborn piglets was substantially higher upon colonization by the nonhaemolytic strain than following inoculation by its wild-type ancestor. We suggest that the E. coli A0 34/86 Delta hlyA mutant may represent a safer prophylactic and/or immunomodulatory tool with unaffected colonization capacity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17064280     DOI: 10.1111/j.1574-695X.2006.00140.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  7 in total

Review 1.  General and molecular microbiology and microbial genetics in the IM CAS.

Authors:  Jan Nešvera
Journal:  J Ind Microbiol Biotechnol       Date:  2010-11-18       Impact factor: 3.346

2.  Quantification of bacterial uropathogens in preclinical samples using real-time PCR assays.

Authors:  Janet L Enderle; Aaron L Miller; Richard B Pyles
Journal:  Curr Microbiol       Date:  2013-10-10       Impact factor: 2.188

3.  The Impact of Escherichia coli Probiotic Strain O83:K24:H31 on the Maturation of Dendritic Cells and Immunoregulatory Functions In Vitro and In Vivo.

Authors:  Lenka Súkeníková; Viktor Černý; Jan Věcek; Petra Petrásková; Olga Novotná; Šimon Vobruba; Tereza Michalčíková; Jan Procházka; Libuše Kolářová; Ludmila Prokešová; Jiří Hrdý
Journal:  Cells       Date:  2022-05-12       Impact factor: 7.666

Review 4.  The RTX pore-forming toxin α-hemolysin of uropathogenic Escherichia coli: progress and perspectives.

Authors:  Travis J Wiles; Matthew A Mulvey
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

5.  Pathogenic potential of Escherichia coli clinical strains from orthopedic implant infections towards human osteoblastic cells.

Authors:  Lise Crémet; Alexis Broquet; Bénédicte Brulin; Cédric Jacqueline; Sandie Dauvergne; Régis Brion; Karim Asehnoune; Stéphane Corvec; Dominique Heymann; Nathalie Caroff
Journal:  Pathog Dis       Date:  2015-09-01       Impact factor: 3.166

6.  Hemolysin of uropathogenic Escherichia coli evokes extensive shedding of the uroepithelium and hemorrhage in bladder tissue within the first 24 hours after intraurethral inoculation of mice.

Authors:  Yarery C Smith; Susan B Rasmussen; Kerian K Grande; Richard M Conran; Alison D O'Brien
Journal:  Infect Immun       Date:  2008-04-28       Impact factor: 3.441

Review 7.  Insights from 100 Years of Research with Probiotic E. Coli.

Authors:  Trudy M Wassenaar
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2016-09-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.